CAMBRIDGE, Mass., Nov. 01, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the 26th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Tuesday, November 7, 2017 at 11:00 a.m. ET / 8:00 a.m. MT.
The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



